NCPA submitted comments to CMS on its calendar year 2026 home health and DMEPOS proposed rule. In the comments, NCPA opposed CMS' proposal to require DMEPOS suppliers to be surveyed and reaccredited every year (as opposed to the current 3-year cycle), due to the increased administrative burden and costs expected for pharmacies, among other reasons.
Additionally, NCPA opposed CMS' proposal to reclassify all continuous glucose monitors (CGMs) and insulin infusion pumps under the DMEPOS competitive bidding program. NCPA also urged CMS to expand access to needed diabetes services by covering CGMs delivered by pharmacists and other qualified practitioners under direct or general (preferable) supervision.
NCPA
